In suspected pheochromocytoma, which functional imaging modality is preferred: 18F‑DOPA PET or 18F‑FDG PET?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

18F-FDOPA PET is the preferred functional imaging modality for suspected pheochromocytoma and paraganglioma

18F-FDOPA PET should be your first-line functional imaging choice when paraganglioma (PGL) is suspected, as it demonstrates higher sensitivity than 123I-MIBG scintigraphy and greater specificity than 18F-FDG PET 1. This recommendation is based on EANM 2012 guidelines which explicitly state that "18F-FDOPA PET is probably the preferred imaging modality when PGL is suspected" 1.

Clinical Context Matters: Tailoring Your Imaging Strategy

The optimal imaging approach depends critically on three factors: genetic status, disease extent (localized vs. metastatic), and tumor location.

For Non-Metastatic Disease

18F-FDOPA PET demonstrates sensitivity approaching 100% for head and neck paragangliomas and maintains excellent performance across most pheochromocytomas 1. Recent meta-analysis confirms 18F-FDOPA has the best overall diagnostic performance with 97% sensitivity and 94% specificity for initial PHEO diagnosis, with diagnostic accuracy of 98.9% 2.

  • For apparently sporadic, non-metastatic pheochromocytomas confined to the adrenal gland, 123I-MIBG is equally sensitive to PET tracers 1
  • Reserve 18F-FDOPA for MIBG-negative cases, multifocal tumors, or when medications interfere with MIBG uptake 1

For Metastatic Disease: Switch to 18F-FDG

The imaging strategy must change dramatically when metastatic disease is present or suspected. 18F-FDG PET becomes the imaging modality of choice for metastatic disease, particularly in SDHB-related tumors 1.

  • 18F-FDG demonstrates 100% detection in metastatic disease 3
  • For SDHB mutations specifically: 18F-FDG shows 83% sensitivity per lesion vs. only 20% for 18F-FDOPA 4
  • 18F-FDOPA sensitivity drops to only 45% in metastatic disease compared to CT/MRI 4

Genetic Status Guides Imaging Selection

If SDHB or VHL mutations are known or suspected, start with 18F-FDG rather than 18F-FDOPA 1. The 2012 EANM guidelines provide a clear algorithm:

  • SDHx-related tumors: 18F-FDG is especially sensitive 1
  • VHL-related tumors: 18F-FDOPA or 18F-FDG 1
  • MEN2-related tumors: 18F-FDOPA preferred (18F-FDG only 40% sensitive) 1
  • Unknown genetic status with extraadrenal/multifocal disease: 18F-FDG first-line 1

Important Caveats and Pitfalls

18F-FDOPA has minimal uptake in normal adrenal glands, making it particularly useful for MEN2-related pheochromocytomas where distinguishing tumor from normal adrenal tissue is challenging 1. This contrasts with 123I-MIBG, where up to 50% of normal adrenal glands show physiological uptake, creating false-positive results 5.

Drug interactions are less problematic with 18F-FDOPA than with 123I-MIBG. MIBG uptake is profoundly affected by sympathomimetics, tricyclic antidepressants, cocaine, calcium channel blockers, and labetalol—requiring 2-week washout periods 5. 18F-FDOPA has fewer such interferences 6.

18F-FDG lacks specificity—it cannot distinguish pheochromocytoma from other FDG-avid tumors, and brown adipose tissue uptake can obscure analysis 6. However, its high sensitivity in aggressive phenotypes (correlating with plasma 3-methoxytyramine levels) makes it invaluable for metastatic disease 3.

The Ideal but Unavailable Option

18F-FDA (fluorodopamine) PET demonstrates the highest sensitivity and specificity across all genetic subtypes (76-78% for metastatic disease) 1, 4, but remains available only at the NIH and is not accessible for routine clinical use 1. When it becomes widely available, it may supersede current recommendations 1.

Practical Algorithm

  1. Start with anatomic imaging (CT/MRI) to identify lesions
  2. For suspected non-metastatic PGL: Use 18F-FDOPA PET
  3. For known/suspected metastatic disease: Use 18F-FDG PET
  4. If SDHB/VHL mutations known: Use 18F-FDG PET regardless of disease extent
  5. If MEN2-related: Use 18F-FDOPA PET (avoid 18F-FDG)
  6. Reserve 123I-MIBG for patients being considered for 131I-MIBG therapy 1

The 2014 Endocrine Society guidelines support this approach, noting that 123I-MIBG is inferior to 18F-FDG PET and 18F-FDOPA for paragangliomas and metastatic disease, particularly in SDHx-related tumors 5.

References

1
Guideline

eanm 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

European Journal of Nuclear Medicine and Molecular Imaging, 2012

5
Guideline

pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2014

Related Questions

What is the optimal imaging study for detecting and localizing a paraganglioma?
What imaging modalities are recommended for localizing a suspected pheochromocytoma?
How should plasma norepinephrine and plasma free metanephrine be collected, processed, and interpreted when evaluating for pheochromocytoma, paraganglioma, or autonomic failure?
What are the clinical features and recommended management for patients with biallelic loss‑of‑function mutations in the PPA2 gene?
To which specialist should a patient with a sialolith be referred?
Can positive intrinsic factor antibodies cause vitamin B12 deficiency?
In a patient with a transient ischemic attack who has discontinued nicardipine and is already on an oral antihypertensive, what medication should be added if the blood pressure remains above 160 mm Hg?
Can anti‑intrinsic factor antibodies also cause folate deficiency?
Does extensive vancomycin use for treating a high prevalence of Clostridioides difficile infection increase the risk of vancomycin‑resistant Enterococcus infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.